Frontlight ResearchEarly access
Not yet recruitingPhase 4
Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years
Key facts
- Who runs it
- Tor Biering-Sørensen
- Where
- Denmark and Spain3 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 410,000 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 30 Sept 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- mCombriax® (mRNA-1083)
- Efluelda® (TIV-HD) and Spikevax® (mRNA-1273)
- Record updated
- 27 August 2026
Who can take part
- Age
- 65 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Age ≥65 years at the time of vaccination
- Self-reported ability to understand written and spoken English or Danish (Denmark only) or Spanish or Galician (Spain only)
- Informed consent form has been signed and dated
Who cannot take part
- There are no specific exclusion criteria for this study
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this pragmatic randomized trials is to evaluate the comparative vaccine effectiveness (cVE) of mCombriax® (mRNA-1083) versus same day co-administration of the active comparators (i.e., high-dose influenza vaccine/Efluelda® and mRNA-1273/Spikevax®) among adults aged 65 years and older.
The 2 groups in the trial
- mCombriax® (mRNA-1083)Treatment being tested
An authorized mRNA-based multicomponent vaccine encoding antigens targeting both seasonal influenza and SARS-CoV-2 viruses.
- Efluelda® (TIV-HD) and Spikevax® (mRNA-1273)Existing treatment, for comparison
Same-day co-administration of an authorized high-dose trivalent influenza vaccine (TIV-HD; Efluelda®) and an authorized COVID-19 mRNA vaccine (Spikevax®, mRNA-1273)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 4, Pragmatic, Randomized Trial to Evaluate the Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years
- Record updated
- 27 August 2026